Elsevier

Biochemical Pharmacology

Volume 45, Issue 10, 25 April 1993, Pages 2045-2053
Biochemical Pharmacology

Induction of cytochrome p450 and peroxisomal enzymes by clofibric acid in vivo and in VITRO

https://doi.org/10.1016/0006-2952(93)90015-OGet rights and content

Abstract

We have analysed the induction of microsomal and peroxisomal proteins and their RNAs after treatment of hepatocytes with the peroxisome proliferator, clofibric acid, in vitro and in vivo. After treatment of hepatocytes with 1 mM clofibric acid for 4 days, P450 4A1 RNA is induced 500-fold, and acyl-CoA oxidase and P450 2B1 280-fold, relative to control cultures. These RNAs are detectably induced after administration of 25 μM clofibric acid, and show a similar induction response with increasing doses of clofibric acid. Western blot analysis of the P450 4A and bifunctional enzyme (BFE) proteins showed that both were induced in parallel with increasing doses of clofibric acid, over a range of 25 μM-1 mM. The distribution of the induced proteins was examined by immunocytochemistry. Increasing doses of clofibric acid led to an increase in the average intensity of staining for both proteins throughout the hepatocyte population. There was, however, a graded variation between hepatocytes in the intensity of staining, both for P450 4A and BFE proteins. The heterogeneity in response of the hepatocyte population in vitro may be related to differential sensitivity of hepatocytes to induction vivo. Therefore, rats were dosed with 0, 50 or 300 mg/kg of clofibric acid for 4 days by gavage, and the livers were examined by immunocytochemistry. After 50 mg/kg of clofibric acid, both P450 4A and BFE were induced mainly in zones 3 and 2 of the liver acinus. However, after 300 mg/kg of clofibric acid, staining for both proteins was strong and homogenous throughout the liver acinus. Thus, hepatocytes from zones 3 and 2 of the acinus are differentially responsive to induction by clofibric acid.

References (22)

  • S Kimura et al.

    The rat clofibrate-inducible CYP4A subfamily II. cDNA sequence of IVA3, mapping of the Cyp4a locus to mouse chromosome 4, and coordinate and tissue-specific regulation of the CYP4A genes

    DNA

    (1989)
  • Cited by (49)

    • Identification, organ expression and ligand-dependent expression levels of peroxisome proliferator activated receptors in grass carp (Ctenopharyngodon idella)

      2012, Comparative Biochemistry and Physiology - C Toxicology and Pharmacology
      Citation Excerpt :

      Clofibrate is a widely used PPARα activator with effects on PPAR activation (Bars et al., 1993; Yaacob et al., 2001). Clofibrate at 0.5–1 mM concentration induces synthesis of acyl-CoA oxidase mRNA, a gene in connection with PPRE (Bars et al., 1993). PPARα mRNA in rat primary hepatocytes is increased when exposed to 0.5 mM of clofibrate (Yaacob et al., 2001).

    • Proteomic mapping of bezafibrate-treated human hepatocytes in primary culture using two-dimensional liquid chromatography

      2011, Toxicology Letters
      Citation Excerpt :

      Interestingly, the expression of cytochrome P450 4A (CYP4A) was not detected as being affected by BEZA treatment in human hepatocytes. This is in line with previous in vivo and in vitro data showing, in contrast to rats in which PPs strongly induced CYP4A protein, human CYP4A is not induced by PPs (Alvergnas et al., 2009; Bars et al., 1993; Cherkaoui-Malki et al., 2001; Richert et al., 2003; Singleton et al., 1999). As expected according to previous reports by us (Richert et al., 1996; Goll et al., 1999, 2000) and others (Léonard et al., 2006; White et al., 2003), no modification of a peroxisomal protein was evidenced in our analysis in human hepatocytes.

    • Gestational and lactational exposure to potassium perfluorooctanesulfonate (K<sup>+</sup>PFOS) in rats: Toxicokinetics, thyroid hormone status, and related gene expression

      2009, Reproductive Toxicology
      Citation Excerpt :

      Chemicals such as Wyeth 14,643, dexamethasone, and phenobarbital are prototypical agonists used to study activation of PPARα, CAR, and PXR receptors, respectively. Wy14,643 induces hepatomegaly that was characterized by peroxisome proliferation and selective induction of Cyp4a1 and Cyp7a1 [68–70]. Dexamethasone produces hepatomegaly as a consequence of extensive periportal fat accumulation and induction of Cyp3a1 [71,72].

    • Peroxisomal proliferator-activated receptor-α-dependent inhibition of endothelial cell proliferation and tumorigenesis

      2007, Journal of Biological Chemistry
      Citation Excerpt :

      In this study, we confirm that Wy-14643, a selective PPRAα ligand, inhibits endothelial cell proliferation and tubulogenesis and, importantly, demonstrate that the functional effects of Wy-14643 are absent in cells from PPARαKO mice and are thus mediated by this nuclear receptor. Because the CYP2C epoxygenases are known PPARα target genes (5–7) and because several reports have characterized the EETs as pro-angiogenic lipids (22–24) and documented the expression of CYP2C epoxygenases in the endothelium (24), we investigated whether the anti-angiogenic effects of Wy-14643 were associated with changes in Cyp2c expression. Three lines of evidence indicate that the anti-angiogenic effects of Wy-14643 result from changes in the expression of Cyp2c epoxygenase isoforms and/or EET levels: (a) phenotype-rescue experiments show that the inhibitory effects of Wy-14643 on endothelial cell proliferation and tubulogenesis can be reversed by the addition of synthetic EETs (Figs. 1 and 3), (b) semi-quantitative RT-PCR analysis of RNAs from endothelial cells cultured in the presence or absence of Wy-14643 showed that the ligand caused marked PPARα-mediated reductions in Cyp2c29, -2c38, and -2c40 epoxygenase transcripts, and (c) Western blots of microsomes from temperature-sensitive immortalized endothelial cells, using anti-Cyp2c44 and anti-CYP2C11 (a rat homologue of murine Cyp2c29, -2c38, and -2c40) antibodies, show that Wy-14643 reduced the cellular levels of anti-CYP2C11 and 2c44 immunoreactive epoxygenase proteins.

    View all citing articles on Scopus

    These authors contributed equally to the contents of the manuscript.

    View full text